FDA-cleared device targets osteopenia with prescription approach as funding aims to expand access, research and commercial reach.
Osteoboost Health is looking to turn the tide on a persistent blind spot in women’s health. The company just closed an $8 million round to scale manufacturing and research for its FDA-cleared wearable, a move that signals more than just a capital injection; it’s a push to finally make osteopenia something more than a “wait and see” diagnosis.
For the 10 million Americans with osteoporosis – and the 44 million more living with low bone density – the current toolkit is alarmingly sparse [1]. The standard of care is notoriously hands-off, leaving millions in a kind of diagnostic limbo while they wait for their condition to worsen. Osteoboost is trying to bridge that gap with a device that sits low on the hips and delivers calibrated vibration therapy to the spine. It seems to be gaining ground, too; with clinical data showing slowed bone density loss and over 2,500 doctors already prescribing it, the company has cleared the regulatory hurdle and is now setting its sights on something much harder: convincing the healthcare system to pay attention.
Longevity.Technology: If Osteoboost’s FDA clearance suggested bone health was edging out of medicine’s aesthetic blind spot, this raise asks a consequential question: can prevention become more than stern advice and a calcium supplement aisle? The company sits in an intriguing, commercially awkward space between consumer wearable and clinical intervention.
Osteopenia has long occupied a therapeutic no-man’s land. It’s serious enough to signal future fracture risk, yet not serious enough for drug treatment, leaving it to drift along on good intentions. Osteoboost’s prescription model challenges that inertia, not by promising a miracle, but by offering a regulated attempt to act early, when biology is still negotiable. That feels notable. So too does the fact that this sits in women’s health – a field often discussed with promising solemnity but funded with less enthusiasm. The harder question now isn’t whether clinicians can be persuaded, but whether payers will follow; prevention is praised in theory, then treated like an optional extra in practice. If longevity is serious about preserving mobility, interventions like this may prove less peripheral than they first appear. We sat down with Osteoboost CEO Laura Yecies to find out more.
Between wellness and medicine
Osteoboost’s positioning is deliberate. “Right now, when a woman is diagnosed with osteopenia, the standard advice is basically ‘exercise more and take calcium,’” Yecies tells us. “That leaves people feeling frustrated and undertreated. It’s a waiting game, a limbo.”
That clinical tension extends beyond bone health. Osteopenia is measurable and predictive, yet it lacks a defined treatment pathway. “That’s exactly where we fit in,” Yecies continues. “Our device is prescribed; it’s FDA-cleared, it’s been through a clinical trial, and it’s not a wellness gadget.”
By pursuing the FDA Class II De Novo pathway, the company bypassed the “wellness” label to establish genuine efficacy. “Our goal is that physicians see it the way they see any other rigorously reviewed prescription treatment,” Yecies says, “a legitimate, evidence-based intervention, without the risk of serious adverse events associated with medications.”
From proxy to outcome
The clinical data focuses on bone density – a proxy for fracture risk. But as Yecies acknowledges, the endpoint that matters is lived experience. “What actually matters is whether someone breaks a hip at 78,” she says. “Hip fractures are devastating; the mortality numbers are terrible, and the cost to the healthcare system is huge.”
This shift – from surrogate marker to tangible outcome – reflects a recalibration within longevity science, prioritizing functional independence over isolated biological metrics. The company is now gathering real-world data to strengthen its case. “We’re collecting real-world outcomes with patient consent,” Yecies notes, “and the case for payers is simple: paying for this upstream is cheaper than treating a fracture later.”
Designing for adherence
Preventive tools live or die by user behavior. Osteoboost’s regimen – 30-minute sessions, three times per week – isn’t onerous, but it isn’t trivial. “The experience is designed to fit seamlessly into the patient’s daily life,” Yecies explains. “They can wear it while going about their day.”
Patterns are emerging. “Patients who stick with it find a routine that works – while walking the dog or using a standing desk,” she says. The company reports an 82% adherence rate in clinical trials [2]. “Motivation is increased for patients who understand their risk and have a doctor who has made clear that this matters.”
Capital, context and constraint
The $8 million raise arrives against an uneven backdrop. Women’s health attracts a fraction of healthcare investment, with funding siloed into reproductive or oncology domains [3]. Devices sit at a further disadvantage, as capital flows toward software and AI.
Yecies is candid about the journey. “Eight years and a lot of persistence,” she says. “AI is taking up almost all the oxygen in venture right now, and women’s health was never the easiest fundraise.”
Yet, the market dynamics are hard to ignore. “This is a massive, underserved market, not a niche,” she argues. Scaling will require more than capital. “We need insurance to cover it,” she says. “Right now, patients pay out of pocket, which limits who can access it.”
There is also a profound research gap. “We need more research focused on women from the start,” she adds. “And we need women to advocate for themselves. Too many of us are accepting frailty as a natural part of aging – I see frailty as something important and absolutely possible to work to prevent.”
Between diagnosis and decline lies a long, passive stretch of time. Interventions like Osteoboost suggest this middle ground may be less fixed than once assumed – a space not simply to observe, but to act. Not dramatic. Not definitive. But perhaps enough.
Photographs courtesy of Osteoboost
[1] https://www.bonehealthandosteoporosis.org/wp-content/uploads/Osteoporosis-Fast-Facts-2.pdf
[2] https://www.osteoboost.com/osteoboost-clinical-trial
[3] https://www.weforum.org/stories/2026/01/women-health-investment-outlook-mapping-opportunity-mobilizing-investment/
